Literature DB >> 23480764

Anti-inflammatory agents suppress the prostaglandin E2 production and migration ability of cholangiocarcinoma cell lines.

Jurairat Jongthawin1, Anchalee Techasen, Watcharin Loilome, Puangrat Yongvanit, Nisana Namwat.   

Abstract

Prostaglandin E2 (PGE2), one of the products catalyzed by cyclooxygenases (COXs), could actuate several pathways implicated in chronic inflammation-related cancer, including apoptosis evasion, cell proliferation, migration and angiogenesis. We hypothesized that blocking of PGE2 production might be an effective strategy to attenuate the progression of cholangiocarcinoma (CCA). Thus, the aim of this study was to examine the effects of two anti-inflammatory agents, meloxicam, a selective COX-2 inhibitor, and xanthohumol, a natural plant extract, on PGE2 production and migration ability of human CCA cell lines. The results showed that 100 μM of meloxicam and 10 μM of xanthohumol suppressed the PGE2 level in the cultured media and wound-induced migration of human CCA cell lines, M139 and M214. The present results revealed that meloxicam and xanthohumol have potential to suppress PGE2 production and cell migration. These findings may offer alternative approaches for chemoprevention and therapy of CCA.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23480764

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  8 in total

1.  Combination of Praziquantel and Aspirin Minimizes Liver Pathology of Hamster Opisthorchis viverrini Infection Associated Cholangiocarcinoma.

Authors:  Pakkayanee Sudsarn; Thidarut Boonmars; Wipaporn Ruangjirachuporn; Nisana Namwat; Watcharin Loilome; Pranee Sriraj; Ratchadawan Aukkanimart; Wonkchalee Nadchanan; Songsri Jiraporn
Journal:  Pathol Oncol Res       Date:  2015-08-16       Impact factor: 3.201

2.  Incidence of renal carcinoma in non-functioning kidney due to renal pelvic stone disease.

Authors:  Kursad Zengin; Serhat Tanik; Nevzat Can Sener; Sebahattin Albayrak; Musa Ekici; Ibrahim Halil Bozkurt; Hasan Bakirtas; Mesut Gurdal; Muhammed Abdurrahim Imamoglu
Journal:  Mol Clin Oncol       Date:  2015-04-24

3.  PGE2 signaling and its biosynthesis-related enzymes in cholangiocarcinoma progression.

Authors:  Jurairat Jongthawin; Porncheera Chusorn; Anchalee Techasen; Watcharin Loilome; Thidarut Boonmars; Raynoo Thanan; Anucha Puapairoj; Narong Khuntikeo; Wichittra Tassaneeyakul; Puangrat Yongvanit; Nisana Namwat
Journal:  Tumour Biol       Date:  2014-05-18

Review 4.  The hop constituent xanthohumol exhibits hepatoprotective effects and inhibits the activation of hepatic stellate cells at different levels.

Authors:  Ralf Weiskirchen; Abdo Mahli; Sabine Weiskirchen; Claus Hellerbrand
Journal:  Front Physiol       Date:  2015-05-06       Impact factor: 4.566

5.  Xanthohumol induces paraptosis of leukemia cells through p38 mitogen activated protein kinase signaling pathway.

Authors:  Xiangquan Mi; Chunming Wang; Chao Sun; Xu Chen; Xiang Huo; Yiming Zhang; Gang Li; Bo Xu; Jun Zhang; Jianxin Xie; Zhenhua Wang; Ji Li
Journal:  Oncotarget       Date:  2017-05-09

6.  Xanthohumol, a Prenylated Chalcone Derived from Hops, Inhibits Growth and Metastasis of Melanoma Cells.

Authors:  Tatjana Seitz; Christina Hackl; Kim Freese; Peter Dietrich; Abdo Mahli; Reinhard Manfred Thasler; Wolfgang Erwin Thasler; Sven Arke Lang; Anja Katrin Bosserhoff; Claus Hellerbrand
Journal:  Cancers (Basel)       Date:  2021-01-29       Impact factor: 6.639

Review 7.  The role of nutrition in influencing mechanisms involved in environmentally mediated diseases.

Authors:  Bernhard Hennig; Michael C Petriello; Mary V Gamble; Young-Joon Surh; Laura A Kresty; Norbert Frank; Nuchanart Rangkadilok; Mathuros Ruchirawat; William A Suk
Journal:  Rev Environ Health       Date:  2018-03-28       Impact factor: 4.022

8.  Antiproliferative and apoptotic effects of xanthohumol in cholangiocarcinoma.

Authors:  Daniel Walden; Selvi Kunnimalaiyaan; Kevin Sokolowski; T Gamblin Clark; Muthusamy Kunnimalaiyaan
Journal:  Oncotarget       Date:  2017-09-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.